Find a Doctor
Eric Haura, MD
Dr. Eric Haura received his undergraduate degree in Biomedical Engineering from the Johns Hopkins University in 1990 and completed medical school at Duke University School of Medicine in 1994. He returned to Johns Hopkins and completed a residency program in internal medicine in 1997. He then went on to Duke to pursue a clinical fellowship in hematology and oncology and a research fellowship in genetics. He completed both programs in 2000. He joined the H. Lee Moffitt Cancer Center and Research Institute in the Department of Thoracic Oncology in 2000 and is currently a Senior Member. He is the Director of the Moffitt Lung Cancer Center of Excellence and is the Co-Program Leader for the Chemical Biology and Molecular Medicine Program. Dr. Haura’s major contribution has been as a leader in advancing the field of translational cancer proteomics and molecular characterization of cancers using highly integrative mass spectrometry-based proteomics. He has characterized protein architectures that regulate tumor growth and response to therapy. He developed approaches to discern mechanisms of complex drugs in cancer allowing repurposing of drugs and expanded uses. He has published more than 100 papers in top-tier scientific journals including Science Signaling, Nature Chemical Biology, Proceedings of the National Academy of Sciences, Molecular Systems Biology, Journal of Clinical Oncology, and Cancer Research. He has received numerous grants through the National Cancer Institute, industry partners, and private foundations. He has served as a consultant for numerous pharmaceutical companies as well as lung cancer research centers. He is a member of the American Association of Cancer Research, the International Association for the Study of Lung Cancer, and the American Society of Clinical Oncology, and the Human Proteome Organization. He has served as a grant reviewer for the National Cancer Institute, American Cancer Society, and private lung cancer research foundations. He received the ASCO Advanced Clinical Research Award in 2007. He was named Moffitt Research Scientist of the Year in 2011 and was named Research Mentor of the Year in 2009. In 2014 he was inducted into the American Society of Clinical Investigation, one of the nation’s oldest and most respected honor societies for physician-scientists. Dr. Haura is an expert in the management of lung cancer. He has designed and executed numerous clinical trials exploring new agents for the treatment of lung cancer. He is interested in biomarkers to predict therapeutic responses in lung cancer and is active in developing molecular based therapeutic clinical trials. He has organized the department’s genome medicine strategy to bring precision medicine to the bedside and is interested in migrating new platforms to the bedside to assist in clinical decision making.
Education & Training
Start Year: 2011 End Year: 2011 Researcher of the Year, Sponsor: H. Lee Moffitt Cancer Center & Research Institute
Start Year: 2003 End Year: 2003 Young Investigator's Award, Sponsor: 10th World Conference on Lung Cancer
Start Year: 2009 End Year: Research Mentor of the Year, Sponsor: Moffitt Cancer Center
CLINICAL TRIAL 19389
CLINICAL TRIAL 19683
CLINICAL TRIAL 19387
CLINICAL TRIAL 21129
CLINICAL TRIAL 20782
CLINICAL TRIAL 21028
CLINICAL TRIAL 20909
CLINICAL TRIAL 21022
Title: Identifying Metabolic Vulnerabilities in Lung Cancer
16 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.Learn more about our patient comments
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including: